We surveyed neuro-oncologists regarding patients treated with temozolomide for at least 12 cycles or 12 months. Patients receiving first-line temozolomide for a median 13 cycles had a median progression-free survival (PFS) of 14 months. Patients with recurrent disease receiving a median 14 cycles had a median PFS of 15.5 months. A small percentage of patients experienced grade III to IV toxicity. These results suggest that long-term treatment with temozolomide is feasible and well tolerated.
A recent joint study by the European Organization for Research and Treatment of Cancer (EORTC) and the National Cancer Institute of Canada (NCIC) demonstrated that temozolomide plus radiotherapy followed by maintenance temozolomide as first-line treatment for glioblastoma (GBM) significantly prolonged survival vs radiotherapy alone. 1 Whereas other regimens with proven efficacy have cumulative toxicities that prevent extension of chemotherapy beyond 5 to 6 cycles, no cumulative toxicity was reported in patients treated with up to 40 cycles of temozolomide. The use of temozolomide for long-term (residual tumor) or maintenance (complete remission) therapy is supported by a 6-month progressionfree survival (PFS) rate of 54% (i.e., at end of chemotherapy) in the EORTC/NCIC trial. 1 However, because chemotherapy was discontinued before disease progression in a substantial proportion of patients, one could hypothesize that the 2-year survival rate of 26% could have been higher if all patients had received temozolomide until disease progression.
In this study, we sought to elucidate the safety and feasibility of long-term treatment with temozolomide and to examine survival outcomes in patients with high-grade glioma who received long-term therapy (at least 12 months or 12 cycles).
Methods. Patients with World Health Organization (WHO)
grade III anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, or WHO grade IV GBM were selected. Only patients who received long-term temozolomide treatment for at least 12 cycles (28 days each) or 12 months were included in the analysis. Contact information for target physicians was extracted from a database of German physicians prescribing temozolomide. Physicians were approached with a standard questionnaire asking for comment on the dose, schedule, number of cycles, and duration of treatment with temozolomide in patients with newly diagnosed and recurrent disease, as well as incidence of WHO toxicity scale grade III or greater leukopenia, thrombocytopenia, gastrointestinal side effects, and infections during treatment with temozolomide. Patients treated either within a prospective clinical trial or in daily clinical practice were included. A subset of investigators also reported survival of their patients. Patients diagnosed between 1997 and 2003 from 50 German centers were reviewed. The primary objective was to evaluate the safety of long-term temozolomide treatment.
Treatment. Patients received oral temozolomide on the standard 5-day regimen (150 to 200 mg/m 2 /day for 5 days in each 28-day cycle) or according to the EORTC/NCIC protocol of concomitant and adjuvant temozolomide, except that temozolomide was continued beyond six cycles until unacceptable toxicity or disease progression occurred.
Patient evaluation. Response evaluation by MRI was performed using the standardized Macdonald criteria. Adverse events that occurred during treatment or after completion of therapy were recorded and graded using the National Cancer Institute Common Toxicity Criteria (version 3).
Statistical analysis. Time to progression (TTP) and overall survival (OS) were calculated from date of diagnosis or initiation 
Results.
Patient characteristics. Of 2,389 physicians polled, 196 responded to the questionnaire, and 50 presented patients (n ϭ 128) who fulfilled the study inclusion criteria. Fifty-five (43%) patients had grade III glioma, and 73 (57%) had grade IV GBM (table). Sixty (47%) patients were treated with temozolomide on a study protocol, and 41 (32%) completed scheduled temozolomide treatment without relapse.
Drug exposure. Patients treated with first-line temozolomide (n ϭ 73) received a median of 13 cycles (range 9 to 40 cycles), and patients treated for recurrent disease (n ϭ 65) received a median of 14 cycles (range 11 to 40 cycles).
Safety. Toxicity data were derived from detailed chart reviews of treating physicians and corresponded well with the low incidence of toxicity reported in prospective clinical trials of temozolomide. However, because of the retrospective nature of this study, the true incidence of toxicity may have been underestimated. Major adverse events of patients included grade III or IV thrombocytopenia (10%), leukopenia (7%), gastrointestinal toxicity (5%), and infection (4%).
TTP and survival. Data were available for a subset of patients. Patients who received first-line temozolomide had a median TTP of 14 months (range 10 to 40 months) from diagnosis, and patients treated for recurrent disease had a median TTP of 15.5 months (range 11 to 44 months) from start of temozolomide treatment. Among 56 patients with survival data available, median OS was 35.1 month (95% CI ϭ 27.8 to 42.3 months) from diagnosis and 25.5 months (95% CI ϭ 20.8 to 30.1 months) from initiation of temozolomide (figure). Median survival from diagnosis was 30.6 months (95% CI ϭ 22.4 to 37.4 months) for GBM patients (n ϭ 35) vs 43.2 months (95% CI ϭ 28.3 to 48.8 months) for patients with grade III anaplastic gliomas (n ϭ 21). From initiation of temozolomide, median survival was 22.4 months (95% CI ϭ 15.7 to 29.2 months) for GBM (n ϭ 19) vs 26.2 months (95% CI ϭ 23.8 to 28.5 months) for anaplastic gliomas (n ϭ 9). The longest survival time among GBM patients was 58.5 months from diagnosis in a patient who received temozolomide as first-line treatment. Another GBM patient who received temozolomide at recurrence survived 66 months from initiation of treatment (after having progressed 8.3 months after initiation of first-line treatment with another regimen). Two years after initial diagnosis, 41 (75%) patients with anaplastic glioma and 50 (68%) patients with GBM remained alive.
Discussion. During the last few years, improved first-line treatment strategies for patients with GBM have increased 1-and 2-year survival rates considerably. 2 Recently, results of the EORTC/NCIC study in patients with newly diagnosed GBM demonstrated 1-and 2-year survival rates of 61 and 26.5%, in patients treated with concomitant radiotherapy (RT) plus daily temozolomide followed by an additional six cycles of temozolomide. 1 As a result, this regimen has become the standard of care for patients with newly diagnosed GBM, and improved first-line PFS rates are expected.
For second-line therapy, pooled data from several phase II studies in GBM patients have demonstrated a median PFS of 2.3 months and a median OS of 6.3 months from time of relapse. 3 The 6-month PFS was 39 to 48% in patients with recurrent high-grade glioma who were treated with alternative combination and dosing regimens of temozolomide. 4, 5 In the current study of patients with high-grade Figure. Kaplan-Meier estimate of overall survival from diagnosis (n ϭ 56) and from initiation of temozolomide treatment for patients with recurrent glioma (n ϭ 28).
glioma, who received up to 40 cycles of temozolomide, first-line treatment lasted up to 40 months, and second-line treatment lasted up to 44 months without signs of tumor progression or cumulative toxicity. Among patients with well-controlled disease and a median OS of Յ58.5 months from diagnosis, temozolomide demonstrated an acceptable safety profile. Therefore, long-term temozolomide therapy appears to be feasible and well tolerated in this patient population. No conclusions can be drawn from the survival data because of the potential selection bias. However, in a recent study that evaluated the correlation between duration of temozolomide therapy (either as a single agent or as part of combination therapy) and PFS in recurrent high-grade glioma, PFS among patients who received 12 to 18 cycles of temozolomide and discontinued treatment in the absence of tumor progression was shorter than for patients who received temozolomide for 19 cycles or more (p ϭ 0.02). 6 This suggests that continued therapy with temozolomide until tumor progression may improve clinical outcomes.
Results from this study showed that long-term administration of temozolomide (Ͼ2,000 cycles of temozolomide) is associated with an acceptable safety profile, regardless of whether temozolomide was administered as first-or second-line therapy. The EORTC/NCIC study demonstrated a 3% incidence of grade III or IV leukopenia; 4% of patients had neutropenia, 3% had thrombocytopenia, and 1% had febrile neutropenia after six cycles of temozolomide on the standard 5-day regimen. 1 Our examination of toxicities for patients receiving at least 12 cycles of temozolomide on the standard 5-day regimen suggests that the incidence of leukopenia was only 7% and thrombocytopenia was only 10%. In addition, the incidence of infections was only 1% with long-term treatment, demonstrating that longer treatment duration does not result in excessive toxicity.
Interestingly, approximately 50% of patients had gross total tumor resections, which is superior to most published trials and consistent with patients in the EORTC/NCIC study. 1 Total resection, shorter delays before initiation of RT, and administration of chemotherapy as first-line treatment may improve long-term survival. [7] [8] [9] Prospective, randomized, controlled studies are needed to evaluate malignant glioma patients with relatively good prognoses who qualify for extended and possibly intensified treatment schedules based on their demographic and molecular characteristics. With this in mind, the number of patients reaching long-term remission after combined first-line therapy could approximate 35 to 50%. In addition, efficacy of long-term treatment with temozolomide in recurrent disease appears promising and provides the rationale for new approaches to treating GBM in relapse.
